Business Wire

SimScale integrates Parasolid and HOOPS Exchange for more powerful 3D CAD handling.

Del

SimScale GmbH (“SimScale”), the provider of the full-cloud engineering simulation platform, today announced a collaboration with Siemens PLM Software and Tech Soft 3D to optimize the simulation workflow through better CAD model handling. SimScale will bring the benefits of Siemens’ Parasolid® software and HOOPS Exchange to a browser-based CAE.

The latest release of SimScale, available shortly, will integrate Parasolid and HOOPS Exchange to enable a more convenient and seamless simulation workflow, while at the same time further increasing simulation result accuracy—both in FEA and CFD.

“Our vision at SimScale is to enable every designer and engineer to take full advantage of engineering simulation—independent of budget, hardware and know-how. This includes seamless interoperability with the customer’s CAD system as well as fast, robust and accurate preparation of CAD data to achieve reliable simulation results quickly. Integrating Parasolid and HOOPS Exchange will help us achieve just that.” said David Heiny, CEO and co-founder of SimScale.

Parasolid is the industry-leading 3D geometric modeling component for computer-aided design, manufacturing and engineering analysis (CAD/CAM/CAE) solutions, while HOOPS Exchange is the leading CAD translation software development kit (SDK). The suppliers of both solutions are continuously innovating in the field of 3d modeling, in order to meet constantly evolving industry trends. This includes building best-in-class solutions for the growing number of cloud-based applications.

“This latest implementation of Parasolid in a cloud-based application will enable engineers to simulate, test and modify 3D models using only a web browser,” says Jim Rusk, chief technology officer, Siemens PLM Software. “In selecting Parasolid, Simscale also obtains translation-free interoperability with hundreds of other applications that integrate Parasolid to design, edit and exchange high-precision 3D models based on the Parasolid XT data format.”

“With the rapid pace of technology advancement, our partners continue to push the boundaries of what’s possible for engineering software development in web technology—our mission is to help them create the best engineering applications in the quickest, easiest way possible,” said Gavin Bridgeman, chief technology officer at Tech Soft 3D. “We are excited about the partnership with SimScale and in particular enabling their customers to bring their CAD data, be it Parasolid-based or otherwise, effortlessly and accurately to the SimScale platform.”

Since the official launch in 2013, SimScale is challenging the “status quo” of the traditional computer-aided engineering (CAE) software market by offering a fully cloud-based engineering simulation solution with zero hardware and software footprint, available at the fraction of the price of its competitors.

“SimScale users have the benefit of a fully collaborative, professional-grade CAE tool covering multiple simulation types powered by unlimited computing power—all via a standard web browser.” said Jon Stevenson, Board Member of SimScale. “The fact that SimScale runs in the cloud enables a broad range of advantages such as multi-user access, collaboration, easy scaling of computing resources, and automated maintenance. ”

SimScale offers a Community plan which is free to all users willing to share their projects publicly. The Professional plan can be tested via a free 14-day trial. Getting started with the trial version only takes a few minutes and requires just a standard web browser.

To learn more about the SimScale pricing plans, visit: https://www.simscale.com/product/pricing/

Note: Parasolid is a trademark or registered trademark of Siemens Product Lifecycle Management Software Inc. or its subsidiaries in the United States and in other countries.

About SimScale:

SimScale is a provider of powerful online 3D simulation technology which is changing the way engineers, designers and students design products. With a founding team of mechanical engineers, computer scientists and mathematicians, SimScale’s goal is to enable everyone to design better products faster and more cost-efficiently by putting engineering simulation tools into the hands of a broader audience. For more information, visit www.simscale.com .

Contact information

SimScale
Agata Krzysztofik
Chief Marketing Officer
+49-89-8091327-65
agata@simscale.com
or
Tech Soft 3D
Angela Simoes
PR Manager
415-302-2934
angela@techsoft3d.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third